This week saw significant rulings from the U.S. Court of Appeals for the Federal Circuit, particularly addressing the discovery expectations in inter partes review (IPR) processes. The court ruled that IPR petitioners are not mandated to supply evidence from related ITC proceedings. Moreover, Broadcom's first quarter strong results were bolstered by high global demand for AI chips, while Novo Nordisk emerged as a leader in the pharmaceutical sector for anti-obesity drug patents. Legislative movement is also highlighted by the CAR Coalition's call for the passage of the REPAIR Act.
The U.S. Court of Appeals for the Federal Circuit clarified that petitioners in Patent Trial and Appeal Board proceedings are not required to provide self-executing discovery from parallel ITC cases.
Strong global demand for AI chips positively influenced Broadcom's first quarter results, showcasing the growing market interest in artificial intelligence technologies.
Novo Nordisk leads global pharmaceutical firms in anti-obesity drug patent filings, indicating a robust competition in the healthcare sector targeting obesity solutions.
The REPAIR Act seeks support from the U.S. House of Representatives, aimed at innovations benefiting the automotive repair sector and strengthening consumer rights.
Collection
[
|
...
]